120 related articles for article (PubMed ID: 25039087)
1. [Active surveillance in prostate cancer. Introduction].
Briones JR
Arch Esp Urol; 2014 Jun; 67(5):367-8. PubMed ID: 25039087
[No Abstract] [Full Text] [Related]
2. Active surveillance monitoring more stringent in updated NCCN Guidelines for prostate cancer.
J Natl Compr Canc Netw; 2011 May; 9(5):xxxvii-xlii. PubMed ID: 21739727
[No Abstract] [Full Text] [Related]
3. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance for prostate cancer: barriers to widespread adoption.
Sandhu GS; Andriole GL
Eur Urol; 2012 Dec; 62(6):984-5. PubMed ID: 22770662
[No Abstract] [Full Text] [Related]
5. Active surveillance for early-stage prostate cancer.
Lancet; 2014 Jan; 383(9913):188. PubMed ID: 24439724
[No Abstract] [Full Text] [Related]
6. Editorial comment. ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.
Bartoletti R; Cai T
Urology; 2011 Mar; 77(3):e1; author reply e2. PubMed ID: 21376994
[No Abstract] [Full Text] [Related]
7. [Editorial. Monographic: Active surveillance in prostate cancer].
Rubio-Briones J; Narbón ES
Arch Esp Urol; 2014 Jun; 67(5):369-71. PubMed ID: 25039088
[No Abstract] [Full Text] [Related]
8. Expectant management for men with early stage prostate cancer.
Filson CP; Marks LS; Litwin MS
CA Cancer J Clin; 2015; 65(4):265-82. PubMed ID: 25958817
[TBL] [Abstract][Full Text] [Related]
9. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric magnetic resonance imaging (MRI) and active surveillance for prostate cancer: future directions.
Mullins JK; Carter HB
BJU Int; 2014 Jun; 113(6):844-5. PubMed ID: 24905655
[No Abstract] [Full Text] [Related]
11. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
Albertsen P
Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
[No Abstract] [Full Text] [Related]
12. More men with low risk prostate cancer are opting for active surveillance, study finds.
BMJ; 2016 Oct; 355():i5688. PubMed ID: 27769959
[No Abstract] [Full Text] [Related]
13. What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer?
Dall'Era M; Carroll P
J Urol; 2015 Sep; 194(3):615-6. PubMed ID: 26079332
[No Abstract] [Full Text] [Related]
14. The economics of active surveillance for prostate cancer.
Dall'Era MA
Curr Opin Urol; 2013 May; 23(3):278-82. PubMed ID: 23449496
[TBL] [Abstract][Full Text] [Related]
15. The inconveniences of active surveillance in prostate cancer.
Sánchez-de-Badajoz E
Actas Urol Esp; 2016 Mar; 40(2):69-71. PubMed ID: 26341888
[No Abstract] [Full Text] [Related]
16. [Economic features of active surveillance].
Huguet J; Musquera M; Ribal MJ; Alcaraz A
Arch Esp Urol; 2014 Jun; 67(5):509-13. PubMed ID: 24914850
[TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer Active Surveillance: Quality Matters.
Van Veldhuizen PJ
J Natl Compr Canc Netw; 2023 May; 21(5):529-530. PubMed ID: 37156479
[No Abstract] [Full Text] [Related]
18. Active surveillance for prostate cancer: the role of the pathologist.
Delahunt B; Hammond E; Egevad L; Samaratunga H; Srigley JR; Humphrey PA; Rubin M; Epstein JI; Lin DW; Gore JL; Nacey JN; Klotz L; Sandler H; Zietman AL; Holden S; Montironi R; Evans AJ; McKenney JK; Berney D; Wheeler TM; Chinnaiyan AM; True L; Knudsen B; Amin MB
Pathology; 2015 Jan; 47(1):1-3. PubMed ID: 25474525
[No Abstract] [Full Text] [Related]
19. [Overdiagnosis in prostate cancer].
Villeda C; Gomez MO; Sotomayor M
Arch Esp Urol; 2014 Jun; 67(5):388-92. PubMed ID: 24914837
[TBL] [Abstract][Full Text] [Related]
20. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer.
Gorin MA; Soloway CT; Eldefrawy A; Soloway MS
Urology; 2011 Mar; 77(3):588-91. PubMed ID: 21215429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
